Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice
4 affiliations
- 1Ministry of Health Holdings Private Limited (MOHH), Singapore 139691, Singapore
- 2Singapore National Eye Centre (SNEC), Singapore 168751, Singapore
- 3Myopia Centre at Bedok, Singapore 460212, Singapore
- 4Singapore Eye Research Institute (SERI), Singapore 169856, Singapore
Abstract
Aim: In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting. Method: Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began. Result: Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age. Conclusions: Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.
Related
- Systematic review of atropine cost-effectiveness in childhood myopia management
- The life course shaping of quality of life in older age: does childhood poverty associate with control, autonomy, self-realisation and pleasure? A retrospective and prospective study of HRS, ELSA, SHARE and TILDA cohorts
- Clinical, immunological, and radiological characteristics of pulmonary involvement in childhood-onset primary Sjögren’s syndrome: a single-center retrospective study
- Interdisciplinary thoraco-plastic surgery for chest wall reconstruction: a clinical practice review based on single-center quality control data.
- Early Postoperative Nausea and Vomiting in Routine Clinical Practice: A Retrospective Observational Study of Associated Perioperative Factors and Prophylactic Practices.
BibTeX
@article{kaiwen2026lowdose,
title = {{Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice}},
author = {Ng Kaiwen and Aaron Qi Yang Goh and Bryan Xiangrong Sim and Sri Yudah and Pauline Poh Lin Chan and Hla Myint Htoon and Audrey Wei Lin Chia},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218587},
url = {https://www.mdpi.com/2077-0383/15/21/8587},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice
AU - Ng Kaiwen
AU - Aaron Qi Yang Goh
AU - Bryan Xiangrong Sim
AU - Sri Yudah
AU - Pauline Poh Lin Chan
AU - Hla Myint Htoon
AU - Audrey Wei Lin Chia
PY - 2026
DA - 2026/11/04
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218587
UR - https://www.mdpi.com/2077-0383/15/21/8587
AB - Aim: In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting. Method: Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began. Result: Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age. Conclusions: Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.
SN - 2077-0383
ER -